Tvardi Therapeutics (TVRD) grants officer 15,000 stock options

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. reported that Principal Accounting Officer Stephen Paul O'Brien received an employee stock option award on January 29, 2026. The option gives him the right to buy 15,000 shares of common stock at an exercise price of $3.90 per share.

The option vests in equal monthly installments over 48 months starting January 29, 2026, so vesting continues as long as he remains in continuous service with the company. The option expires on January 29, 2036, and all 15,000 derivative securities are reported as directly owned after this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider O'Brien Stephen Paul

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	15,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 15,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Brien Stephen Paul

(Last) (First) (Middle)

C/O TVARDI THERAPEUTICS, INC.

3 SUGAR CREEK CTR BLVD, STE 525

(Street)

SUGAR LAND TX 77478

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tvardi Therapeutics, Inc. [ TVRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$3.9	01/29/2026		A		15,000		(1)	01/29/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. The shares subject to the option shall vest and become exercisable in equal monthly installments over 48 months commencing on January 29, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

	/s/ Dan Conn, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tvardi Therapeutics (TVRD) report for Stephen Paul O'Brien?

Tvardi Therapeutics reported that Principal Accounting Officer Stephen Paul O'Brien received an employee stock option grant for 15,000 shares on January 29, 2026. These are derivative securities giving him the right to buy common stock under the company’s equity compensation arrangements.

What are the key terms of Stephen Paul O'Brien's Tvardi (TVRD) stock options?

The options allow Stephen Paul O'Brien to purchase 15,000 shares of Tvardi common stock at an exercise price of $3.90 per share. They were granted on January 29, 2026 and are structured as employee stock options with a long-term expiration in 2036.

How do Stephen Paul O'Brien’s Tvardi (TVRD) options vest over time?

The 15,000 options vest in equal monthly installments over 48 months beginning January 29, 2026. Vesting is conditioned on his continuous service with Tvardi through each monthly vesting date, so unvested portions depend on ongoing employment.

When do Stephen Paul O'Brien’s Tvardi Therapeutics (TVRD) options expire?

The employee stock options granted to Stephen Paul O'Brien expire on January 29, 2036. This gives a 10-year term from the January 29, 2026 grant date, during which vested options may be exercised at the stated $3.90 per share exercise price.

How many Tvardi (TVRD) derivative securities does Stephen Paul O'Brien own after this Form 4?

After the reported transaction, Stephen Paul O'Brien beneficially owns 15,000 derivative securities in the form of employee stock options. These options are reported as directly owned and correspond to 15,000 underlying shares of Tvardi common stock, subject to vesting.